Abbott Updates Heart Failure Management by Excluding Aspirin for Patients with the HeartMate 3 Heart Pump
Shots:
- Based on the ARIES-HM3 study data, Abbott reported that the US FDA approved a label change for patients with HeartMate 3 left ventricular assist device (LVAD), removing Aspirin from the patient management regimen, and this change is also approved by Canada and the EU regulatory
- The study evaluated Aspirin (100 mg/day) vs PBO + vitamin K antagonist (VKA) therapy in adults (≥18 years) with advanced heart failure who were newly implanted with Abbott's HeartMate 3 LVAD
- The study met 1EP by demonstrating patients receiving VKA spent 47% fewer days in the hospital due to 40% decrease in bleeding events with no elevated risk of developing thrombosis
Ref: Abbott | Image: Abbott
Related News: Abbott Reports (MOMENTUM 3) Trial Results of HeartMate 3 Heart Pump for the Treatment of Advanced Heart Failure
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
